In silico single and double docking antioxidant and antidiabetic potential of EGCG and Bacoside-A

Abstract

Undoubtedly, Diabetes mellitus is one of the alarming health challenge to the society. From the past decade, prevalence rate of diabetes mellitus has increased dramatically. Diabetes mellitus was 8.3% prevalent in 2012, with 371 million people living with the disease.he number of carriers is expected to reach 552 million by 2020. According to data available in literature shows that oxidative stress plays crucial role in diabetic pathogenesis that leads to the generation of various other health associated complications. Scientists are now focussing their attention upon discovering new and innovative ways to lower the danger of oxidative damage. For the past three decades, Diabetes mellitus (DM) has been the primary source of major global economic burden. According to the International Diabetes Federation (IDF), diabetes would affect 642 million people aged 20 to 79 years old by 2050. For the past three decades, Diabetes mellitus (DM) has been the primary source of major global economic burden. According to the International Diabetes Federation (IDF), diabetes would affect 642 million people aged 20 to 79 years old by 2050.To avoid chronic non-communicable illness, the prevalence and fatalities associated with diabetes continue to rise globally; properly planned surveillance and prevention actions must be estimated globally. The speed and cost-effectiveness of innovative drug development is aided by computational research approaches. The characteristics of pharmaceutical chemicals have been improved in recent years based on predictions of absorption, distribution, metabolism, excretion, and toxicity (ADMET). EGCG and Bacoside A were analysed in silico in this study. OSIRIS and MoLSoFT are used to analyse a variety of molecular descriptors such as physicochemical qualities, solubility, drug score, and toxicity predictions. Using drug docking approach, powerful drug interactions have also been discovered.